Overview

Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function

Status:
Completed
Trial end date:
2020-09-11
Target enrollment:
Participant gender:
Summary
Evaluation of the pharmacokinetics (PK) of TBPM-PI-HBr in subjects with normal renal function, subjects with various degrees of renal insufficiency, and subjects with end-stage renal disease (ESRD) receiving hemodialysis (HD) therapy.
Phase:
Phase 1
Details
Lead Sponsor:
Spero Therapeutics